{"id":649845,"date":"2023-05-01T15:46:01","date_gmt":"2023-05-01T15:46:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=649845"},"modified":"2023-05-01T15:46:01","modified_gmt":"2023-05-01T15:46:01","slug":"acute-myeloid-leukemia-market-analysis-epidemiology-analysis-pipeline-insights-companies-working-are-actinium-pharmaceuticals-aveo-oncology-and-biodesix-rafael-pharmaceuticals-biosight-bergenb","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/acute-myeloid-leukemia-market-analysis-epidemiology-analysis-pipeline-insights-companies-working-are-actinium-pharmaceuticals-aveo-oncology-and-biodesix-rafael-pharmaceuticals-biosight-bergenb_649845.html","title":{"rendered":"Acute Myeloid Leukemia Market Analysis, Epidemiology Analysis, Pipeline Insights | Companies working are Actinium Pharmaceuticals, AVEO Oncology and Biodesix, Rafael Pharmaceuticals, BioSight, BerGenB"},"content":{"rendered":"
\n
\"Acute<\/a><\/div>\n
\n
Acute Myeloid Leukemia Market<\/div>\n<\/div>\n<\/div>\n
DelveInsight\u2019s \u2018Acute Myeloid Leukemia Market Insights, Epidemiology, and Market Forecast\u20142032\u2019 report delivers an in-depth understanding of the Acute Myeloid Leukemia (AML), historical and forecasted epidemiology as well as the market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.<\/div>\n

DelveInsight has launched a new report on “Acute Myeloid Leukemia – Market Insights, Epidemiology, and Market Forecast-2032”.<\/strong>
<\/a><\/p>\n

DelveInsight’s “Acute Myeloid Leukemia – Market Insights, Epidemiology, and Market Forecast-2032″<\/a><\/strong> report delivers an in-depth understanding of the Acute Myeloid Leukemia, historical and forecasted epidemiology as well as the Acute Myeloid Leukemia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n

Some of the key facts of the Report:<\/strong><\/p>\n

    \n
  1. AML accounts for <3% of all cancers, and 25% of all leukemia in adults. Worldwide, the incidence of AML was reported to be highest in the US, Australia, and Western Europe. The incidence has been near stable over the last years.<\/li>\n
  2. The Surveillance has reported an AML incidence rate of 3.7 per 100,000 inhabitants in Europe with a 5-year survival rate of 19%.<\/li>\n<\/ol>\n

    Key benefits of the report:<\/strong><\/p>\n

      \n
    1. Acute Myeloid Leukemia market report covers a descriptive overview and comprehensive insight of the Acute Myeloid Leukemia Epidemiology and Acute Myeloid Leukemia  market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)<\/li>\n
    2. The Acute Myeloid Leukemia market report provides insights on the current and emerging therapies.<\/li>\n
    3. Acute Myeloid Leukemia market report provides a global historical and forecasted market covering drug outreach in 7MM.<\/li>\n
    4. The Acute Myeloid Leukemia market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Acute Myeloid Leukemia market.<\/li>\n<\/ol>\n

      Got queries? Click here to know more about Acute Myeloid Leukemia Market Landscape.<\/a><\/strong><\/p>\n

      Acute Myeloid Leukemia Overview<\/strong><\/p>\n

      Acute myelogenous leukemia (AML) is a cancer of the blood and bone marrow — the spongy tissue inside bones where blood cells are made. The word “acute” in acute myelogenous leukemia denotes the disease’s rapid progression. It’s called myelogenous leukemia because it affects a group of white blood cells called the myeloid cells, which normally develop into the various types of mature blood cells, such as red blood cells, white blood cells, and platelets.<\/p>\n

      The key players involved in the Acute Myeloid Leukemia market:<\/strong><\/p>\n